A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
about
Angiogenesis-inhibitors for metastatic thyroid cancerThe role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsChemotherapy and chemoprevention by thiazolidinedionesCommonalities in the Association between PPARG and Vitamin D Related with Obesity and CarcinogenesisAlternative medical treatment for radioiodine-refractory thyroid cancers.Multi-targeted approach in the treatment of thyroid cancer.Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinomaComparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases.Peroxisome proliferator-activated receptors and cancer: challenges and opportunitiesEmerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.Standard and emerging therapies for metastatic differentiated thyroid cancer.PPARγ Promotes Growth and Invasion of Thyroid Cancer CellsDifferentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.PPARgamma and MEK Interactions in CancerTo Live or to Die: Prosurvival Activity of PPARgamma in Cancers.Molecular genetics of papillary thyroid carcinoma: great expectations.Thiazolidinediones as anti-cancer agents.Clinical Use of PPARgamma Ligands in Cancer.PPAR Ligands for Cancer Chemoprevention.Protective Effect of PPARγ Agonists on Cerebellar Tissues Oxidative Damage in Hypothyroid Rats.Clinicopathologic and molecular disease prognostication for papillary thyroid cancer.Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas.Targeted molecular therapies in thyroid carcinoma.Membrane Proteins Involved in Epithelial-Mesenchymal Transition and Tumor Invasion: Studies on TMPRSS4 and TM4SF5.Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?New therapeutic options for advanced forms of thyroid cancer.The multifaceted factor peroxisome proliferator-activated receptor γ (PPARγ) in metabolism, immunity, and cancer.Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.New insights into antidiabetic drugs: Possible applications in cancer treatment.PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments.The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer.Soft tissue metastases from differentiated thyroid cancer diagnosed by ¹⁸F FDG PET-CT.Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy.Novel targeted therapies and immunotherapy for advanced thyroid cancers.Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
P2860
Q24236743-19379111-51B5-4FB5-815D-F274BE7FEB78Q24601222-C5616805-1708-44A0-8D1B-BA15B795FF6FQ26863326-492EBCF4-3CAF-4BCF-9923-F82807106CE6Q27011352-6D8E3FA6-34C6-44B8-A296-882099428A78Q28070220-2ED507A2-0260-4F39-8ED3-75720087F965Q33704599-222317DC-EE48-47F2-BCD2-B00EC3217ECFQ33982413-D48F28BD-4537-4B1D-9B42-F5F46C71EFF4Q34318833-274B7DE7-484B-4C97-A52A-0D1630B740F5Q35007015-36C3BB54-C7A0-4E34-8083-8A145B04D5C8Q35210023-094DFDE8-FFF4-472C-BE79-A5C87EA6913FQ35370655-28290799-9C04-4000-91F1-0C993CF3C65AQ35583906-35BA867C-BC66-4DAD-81F5-C0B7153E74B2Q35608757-FDDEDD1C-BF17-4E9F-8535-34B1FDF9B47EQ35864072-B866EBF1-FBD5-4529-AE77-D938EEB5B3A9Q36737285-B1B15E52-6632-4C07-89AF-876F4B6B2B3EQ36867693-904EDC01-0040-4D80-888F-D9462BFA93DEQ36949765-F63A8C3B-5276-4786-95FE-BFC10DA254BCQ37010188-99545E54-9E08-4BC5-AD45-46124300029FQ37021288-74EF5676-E5BA-42D7-B96B-F29DAAC618CCQ37165190-AE85AB93-6E8D-4407-B65D-8F719DAB2BA6Q37571681-4FB52C03-5B7B-4D1F-A607-7A14367584B8Q37598938-46897213-DAE7-48EE-9F7E-6CB10BF59956Q37606299-07E9BDFF-6BB0-4469-840E-D93C1BF51CEAQ37686162-FDB6E55F-6C06-4E5C-BCE4-1DAFE4041E4CQ37709042-A0765F0C-8408-4C8E-AFEA-9B5340CDB23DQ37924944-C36CC040-F7AE-4F7C-9D5F-DB75071FBF76Q38192680-BC5A9A64-5384-4F2D-BEF9-DD847E45BB41Q38314756-048EAE2D-152D-4708-91E6-91D0D961CBFEQ39041602-2F4E735C-E1A8-47BD-A88D-D63C1D460709Q39272833-EEA9D091-84AF-47E6-AD0F-725B38CDA6CBQ39609137-1A149F28-FCD5-418A-A3BE-608B28AB88F8Q41677812-10FA426F-A032-4750-8B37-0C097ED6A51FQ42023771-B1B52B36-504B-4483-8E02-30393B688F65Q44448524-8F1A108A-4A73-49C1-ADFE-E89DC494B173Q46073511-2A52615E-9BBC-4296-BEEE-48EE5380A430Q49887965-BCDCDF68-A954-456F-B052-5D8DC125330CQ53060957-ED429BDC-FA66-41B1-95C0-2B2D88121CB7
P2860
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A phase II trial of rosiglitaz ...... differentiated thyroid cancer.
@en
A phase II trial of rosiglitaz ...... differentiated thyroid cancer.
@nl
type
label
A phase II trial of rosiglitaz ...... differentiated thyroid cancer.
@en
A phase II trial of rosiglitaz ...... differentiated thyroid cancer.
@nl
prefLabel
A phase II trial of rosiglitaz ...... differentiated thyroid cancer.
@en
A phase II trial of rosiglitaz ...... differentiated thyroid cancer.
@nl
P2093
P1433
P1476
A phase II trial of rosiglitaz ...... differentiated thyroid cancer.
@en
P2093
Electron Kebebew
Eugene Morita
Francis S Greenspan
Kenneth A Woeber
Orlo H Clark
Patrick Treseler
Quan-Yang Duh
Sheila Lindsay
P304
960-6; discussion 966-7
P356
10.1016/J.SURG.2006.07.038
P407
P50
P577
2006-12-01T00:00:00Z